[go: up one dir, main page]

WO2015026708A3 - Amelioration of the effects of friedriech's ataxia - Google Patents

Amelioration of the effects of friedriech's ataxia Download PDF

Info

Publication number
WO2015026708A3
WO2015026708A3 PCT/US2014/051454 US2014051454W WO2015026708A3 WO 2015026708 A3 WO2015026708 A3 WO 2015026708A3 US 2014051454 W US2014051454 W US 2014051454W WO 2015026708 A3 WO2015026708 A3 WO 2015026708A3
Authority
WO
WIPO (PCT)
Prior art keywords
ataxia
effects
friedriech
amelioration
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/051454
Other languages
French (fr)
Other versions
WO2015026708A2 (en
Inventor
Robert B. Wilson
M. Grazia COTTICELLI
Andrew M. CRABBE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of WO2015026708A2 publication Critical patent/WO2015026708A2/en
Publication of WO2015026708A3 publication Critical patent/WO2015026708A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The effects of Friedreich's Ataxia are ameliorated by administering to a patient known or suspected of having the disease with essentially free cis Δ9 fatty acid having from 12 to 24 carbon atoms and a single double bond in a cis configuration at the C9 carbon atom. Dosage regimes and kits are also featured.
PCT/US2014/051454 2013-08-20 2014-08-18 Amelioration of the effects of friedriech's ataxia Ceased WO2015026708A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361867727P 2013-08-20 2013-08-20
US61/867,727 2013-08-20

Publications (2)

Publication Number Publication Date
WO2015026708A2 WO2015026708A2 (en) 2015-02-26
WO2015026708A3 true WO2015026708A3 (en) 2015-11-19

Family

ID=52484256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/051454 Ceased WO2015026708A2 (en) 2013-08-20 2014-08-18 Amelioration of the effects of friedriech's ataxia

Country Status (1)

Country Link
WO (1) WO2015026708A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20090291092A1 (en) * 2008-05-22 2009-11-26 Miller Guy M Treatment of mitochondrial diseases with an erythropoietin mimetic
EP2272383A1 (en) * 2009-06-22 2011-01-12 SBAE Industries NV Composition Comprising Omega-7 and/or Omega-4 Fatty Acids
US20120040014A1 (en) * 2010-08-12 2012-02-16 Robert Settineri LIPID Supplements for Maintaining Health and Treatment of Acute and Chronic Disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20090291092A1 (en) * 2008-05-22 2009-11-26 Miller Guy M Treatment of mitochondrial diseases with an erythropoietin mimetic
EP2272383A1 (en) * 2009-06-22 2011-01-12 SBAE Industries NV Composition Comprising Omega-7 and/or Omega-4 Fatty Acids
US20120040014A1 (en) * 2010-08-12 2012-02-16 Robert Settineri LIPID Supplements for Maintaining Health and Treatment of Acute and Chronic Disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAVARRO, JA: "Altered Lipid Metabolism in a Drosophila Model of Friedreich's Ataxia.", HUMAN MOLECULAR GENETICS., 2010, pages 1 - 13, XP055236237 *

Also Published As

Publication number Publication date
WO2015026708A2 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
PH12020550768A1 (en) Compositions and methods of use of phorbol esters
MX2022007264A (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof.
MX2013010343A (en) COMPOSITION AND METHODS FOR THE TRANSPLANT OF MICROBIOTA DE COLON.
MX2009010977A (en) Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
DOP2015000012A (en) 5-AMINOTETRAHYDROQUINOLIN-2-NEW CARBOXYL ACIDS AND THEIR USE
CR20130259A (en) 1-BENCILCICLOALQUILCARBOXÍLICOS ACIDS SUBSTITUTED AND ITS USE
EA201201281A1 (en) ENHANCEMENT OF DIETS OF MOTHERS WITH SIAL ACID
IN2014DN05986A (en)
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
WO2013116753A8 (en) Fatty acids as anti-inflammatory agents
MX2013002725A (en) Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle.
WO2012158780A3 (en) Lung cancer signature
CO7160080A2 (en) Lipid compositions of racecadot
BR112014003640A2 (en) weight loss methods and ketogenic compositions
CL2017001375A1 (en) Methods of therapeutic monitoring of prodrugs of phenylacetic acid.
PH12013500917A1 (en) Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions
MX2015013739A (en) Glycogen-based water solubility enhancers.
WO2015026708A3 (en) Amelioration of the effects of friedriech's ataxia
WO2015023631A3 (en) Fatty acid analogs and their use
WO2012112862A3 (en) Treating mycobacterial infection with cu+/++ boosting therapeutics
PH12018500076A1 (en) Prophylaxis of hypertension and cardiovascular diseases
BR112014019486A8 (en) USE OF A NON-DIGERABLE OLIGOSACCHARIDE AS A MATERNAL SUPPLEMENT
Joseph Tooth wear and dentures
UA68764U (en) Method to improve contractile function of beef cow uterus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14837937

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14837937

Country of ref document: EP

Kind code of ref document: A2